Diagnosis of neural crest tumors by reversed-phase high-performance liquid chromatographic determination of urinary catecholamine metabolites.
Aberrations in the metabolic pathways of catecholamines in patients with neural crest tumors result in characteristic urinary excretion patterns of their catabolites. Tumors such as pheochromocytoma, neuroblastoma and ganglioneuroma usually defy clinical diagnosis because of their rarity, small size, intraabdominal position and clinical symptoms similar to those of essential hypertension. Quantitative determination of catecholamine metabolites such as vanillylmandelic acid (VMA) and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) offers possibilities for reliable confirmation of diagnosis. However, previous techniques for the assessment of catabolite levels suffered from inadequate sensitivity, reproducibility or specificity, which seriously diminished their usefulness as biochemical determinants in the prognosis of these life-threatening tumors. Reported in this paper is the analysis of urinary levels of VMA and MHPG using reversed-phase high-performance liquid chromatography with electrochemical and sectrophotometric detection. We present the excretion patterns showing these metabolites in 15 control subjects, 15 patients with pheochromocytoma and 5 patients with neuroblastoma.
D002395:Catecholamines / Q000378:metabolism / Q000652:urine*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005260:Female; D005315:Fetal Diseases / Q000652:urine; D006801:Humans; D009432:Neural Crest; D009447:Neuroblastoma / Q000196:embryology / Q000378:metabolism / Q000652:urine*; D010673:Pheochromocytoma / Q000196:embryology / Q000378:metabolism / Q000652:urine*; D011247:Pregnancy
D002395:Catecholamines